| Objective To explore the creative effect of small dose of azithromycin with symbicort turbuhaler in the treatment of patients with chronic obstructive pulmonary disease (COPD) at stable phase. Methods A total of 120 patients with stable COPD were selected in Suixi County hospital from May 2013 to April 2015, and were randomized into group A (control group, 25 cases), conventional treatment group B (oral azithromycin, 250 mg/, 32 cases); group C (symbicort turbuhaler, i.e. 160 g/absorption of budesonide formoterol+45 μg/1/suction, 32 cases), and group D (250mg; oral azithromycin combined with inhaled symbicort, with the same dose as before, 31 cases). The course of treatment was half a year and the follow-up lasted half a year. The levels of C reactive protein (CRP), plasma soluble glycation end products (sRAGE) and advanced glycation end products (AGEs) were compared between the four groups before and after treatment. The improvement of pulmonary function, daily spitting, the rate of bacterial positive, curative effect and acute exacerbation times for all patients before and after treatment were contrasted as well. Results Compared with pre-treatment, the content of CRP and AGEs decreased significantly in group B, C, D after treatment, while sRAGE increased (P<0.05). The lung function was greatly improved in group D, Daily spitting volume and the times of acute exacerbation were significantly reduced, and bacterial positive rate decreased markedly (P<0.05). The total efficiency was up to 90.32% in group D, significantly greater than azithromycin alone or simply symbicort treatment group (P<0.05). Conclusion Low dose azithromycin combined with symbicort is effective in the treatment of patients with stable COPD, with apparent improvement in the lung function of patients. |
